NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Leo I. Gordon(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Jeremy S. Abramson(Massachusetts General Hospital), Ranjana H. Advani(Cancer Institute (WIA)), Nancy L. Bartlett(Barnes-Jewish Hospital), Paolo F. Caimi(Cleveland Clinic), Julie Chang(University of Wisconsin Carbone Cancer Center), Julio C. Chávez(Moffitt Cancer Center), Beth Christian(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Luis Fayad(The University of Texas MD Anderson Cancer Center), Martha Glenn(University of Utah), Thomas M. Habermann, Nancy L. Harris(Barnes-Jewish Hospital), Francisco J. Hernandez‐Ilizaliturri(Novartis (Switzerland)), Mark Kaminski(University of Michigan), Chris R. Kelsey(Cancer Institute (WIA)), Nadia Khan(Fox Chase Cancer Center), Susan Krivacic(Marymount University), Ann S. LaCasce(Dana-Farber Brigham Cancer Center), Amitkumar Mehta(University of Colorado Cancer Center), Auayporn Nademanee(City Of Hope National Medical Center), Rachel Rabinovitch(University of Colorado Cancer Center), Nishitha Reddy(Novartis (Switzerland)), Erin Reid(University of California San Diego), Kenneth B. Roberts(Smilow Cancer Hospital), Stephen D. Smith(Seattle Cancer Care Alliance), Erin D. Snyder(University of Colorado Cancer Center), Lode J. Swinnen(Sidney Kimmel Comprehensive Cancer Center), Julie M. Vose(Novartis (Switzerland)), Mary A. Dwyer(National Comprehensive Cancer Network), Hema Sundar(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
June 1, 2019
10.6004/jnccn.2019.0029
Cited by 189Open Access
Full Text

Abstract

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

Related Papers

No related papers found

Powered by citation graph analysis